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Abstract 
The ability to rationally manipulate and augment the cytoplasmic membrane can be used to 
overcome many of the challenges faced by conventional cellular therapies, and provide 
innovative opportunities when combined with new biotechnologies. The focus of this review 
is on emerging strategies used in cell functionalization, highlighting both pioneering 
approaches and recent developments. These will be discussed within the context of future 
directions in this rapidly evolving field. 
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Introduction 
The demand for cell functionalization 
New biotechnologies, such as organ-on-a-chip1 and 3D bioprinting,2 are providing 
researchers with increasingly innovative approaches to studying disease, engineering tissue 
and promoting in vivo regeneration. These biotechnologies often demand unnatural 
functions from cells, for instance, in cell therapy we would ideally like to target cells to a 
particular area of the body, often to promote an unnatural response within a hostile 
environment, while being able to visualise the entire process in vivo.3,4 Cells were never 
intended for use in allogeneic therapy,5 nor were tissues meant to be engineered in an 
incubator,6 or embryos in a test tube.7 Such applications are greatly removed from how a 
cell is programmed to function within an organism, which limits cells to pre-defined functions 
(e.g. cell-specific signaling pathways8 and surface markers9) and imposes tight constraints 
based on physiological conditions (e.g. temperature10 and oxygen tension11). Indeed, we 
are now at a stage where the cell itself could be considered the major restrictive factor, thus, 
effective methods to re-engineer cells are required to keep up with the rapid pace of 
biotechnological development. 
An emerging strategy to overcome these limitations is cytoplasmic membrane modification, 
which can be used to either supplement the existing capabilities of a cell, or provide entirely 
new, non-native functionality. This cell functionalization approach has allowed us, for 
instance, to provide cells with additional binding sites12 and nutrients,13 protection in harsh 
environments,14 increased adhesion to scaffolds15 and magnetic contrast.16 Compared to 
genetic modification, these strategies are simpler, faster and can be used to deliver a greater 
variety of materials to a wider range of cells. The scope of this review will cover both the 
active and passive delivery of soft biomaterials (e.g. proteins, biopolymers and 
carbohydrates) with a specific focus on non-specific membrane binding and instances where 
cells have been augmented with added functionality. We will present a selection of both 
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pioneering and recent approaches to cell functionalization, discuss their relative merits, and 
conclude by considering the challenges and future directions of this exciting new field. 
The cell membrane as an addressable canvas 
The cytoplasmic membrane was first identified by Wilhelm Pfeffer in 1877, who proposed a 
membrane theory that suggested cells were filled with an aqueous solution contained by a 
physical, semi-permeable barrier.17  In 1925, Gorter and Grendel famously used a Langmuir 
trough to demonstrate that the cytoplasmic membrane of erythrocytes was only two 
molecules thick.18 This led to the well-recognised phospholipid bilayer model, in which the 
cytoplasmic membrane was considered a lamellar bilayer stabilized by hydrophobic 
interactions between the fatty acid tails of the constituent phospholipids. It is now known that 
up to 1000 different lipids contribute to the bilayer structure, which has a thickness of 
approximately 75 Å.19 This lipid sandwich supports a wide array of proteins, which can be 
embedded within the bilayer (integral), loosely-bound to the surface (peripheral) or attached 
via a lipid anchor (lipid-bound). This was elegantly portrayed in Singer and Nicolson's fluid 
mosaic model in 1972, which depicted proteins laterally diffusing throughout a dynamic 
phospholipid bilayer, considered to be an isotropic fluid.20 An important advance on this 
model was the incorporation of lipid microdomains, which were proposed as non-equilibrium, 
two-dimensional aggregates of phospholipids and proteins, essential in membrane 
trafficking and turnover.21 Finally, an often overlooked component of the cytoplasmic 
membrane is the glycocalyx, a layer of glycans present on the outer membrane leaflet that 
is used by cells to interact with the extracellular environment.22 These components form the 
basis of the current understanding of the cytoplasmic membrane structure. 
A cell biologist will (correctly) consider the phospholipid bilayer a protective structural barrier, 
with the proteins and carbohydrates as functional components regulating mass transport,23 
adhesion24 and signalling.25 An alternative view of the cytoplasmic membrane is that of a 
canvas of addressable molecules and moieties, which can be exploited as targets for cell 
functionalization. Carolyn Bertozzi memorably described the cell membrane as a “sea of 
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functionality”,26 and when viewed from this perspective, the phospholipid bilayer becomes a 
dynamic hydrophobic continuum into which lipid anchors may be inserted, while proteins, 
glycans and phospholipid head groups are simply a collection of chemically addressable 
functional groups. Having said this, a multitude of factors must be considered when 
designing a cell surface modification strategy. First and foremost is the maintenance of cell 
viability, which necessitates functionalization methodologies that employ aqueous 
conditions, physiological pH and ionic strength, as well as ambient temperature and 
pressure. Even under these cell-amenable conditions, the introduction of membrane-active 
chemical species can still lead to cytotoxicity through processes such membrane thinning 
or hole formation,27 while blocking or modifying specific glycans can also be detrimental to 
cell function. Secondly, the temporal persistence of the exogenous material must be 
considered. Unlike genetic modification, which can be used for long-term transgene 
expression, cell functionalization strategies are intrinsically transient due to membrane 
turnover and mitosis that continuously dilute membrane-bound species. Finally, the spatial 
location and orientation of the membrane guest molecule can be important for certain 
applications, for instance, a targeting antibody may require a linker to project it away from 
the membrane surface into extracellular space, while a receptor protein or glycan will need 
to transduce signals across the membrane bilayer. Fortunately, there exists an array of well-
developed cell functionalization strategies that cater to different, individual requirements. 
The remainder of this review will discuss the relative merits and notable successes of three 
broad approaches; cell surface chemistry, non-covalent membrane labelling and extended 
cellular coating (Figure 1). 
Covalent cell surface chemistry & bio-orthogonal labelling 
Designing chemical syntheses under cytocompatible conditions is challenging, as cell 
viability has to be prioritized over more common objectives, such as reaction yield and rate. 
With this in mind, an attractive strategy is to use bio-inspired enzymatic reactions that have 
evolved to work under physiological conditions. For example, the McEver and Wohlgemuth 
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Groups used α-1,3-fucosyltransferase to enzymatically modify selectin ligands with 
guanosine diphosphate fucose, in order to present the glycoprotein sialyl Lewis X (sLeX) on 
cord blood cells31 and human mesenchymal stem cells (hMSCs).32 Here, promoting the 
surface expression of sLeX was shown to mediate a non-native cell rolling response to 
endothelial selectins. Cell rolling was also targeted by the Karp Group in 2008, who used 
biotinylation of cell-surface amines to streptavidin-link biotinylated sLeX (Figure 2a). This 
report was preceded by a very similar “ProtEx” technology, developed by the Shirwan Group 
in 2005,33 which showed that streptavidin fusion proteins could persistently label cells in vitro 
and in vivo. This approach has been used to enhance graft survival with CD95L34,35, inhibit 
cancer cell growth with CD8036,37, and produce whole-cell vaccines bearing GM-CSF / TNFα 
co-stimulators.38 Despite being less abundant than amines, thiol groups present on cysteine-
bearing proteins are an attractive target for cell surface chemistry, and their capacity for click 
chemistry reactivity has been used, for instance, in the binding of maleimide-functionalized, 
drug-loaded liposomes.39 Overall, these direct cell surface modifications represent an 
excellent approach, albeit one that is restricted by constrained reaction conditions and a 
limited number and range of addressable groups. 
A major breakthrough in this field was the development of “bio-orthogonal” chemistry, which 
was pioneered by the Bertozzi Group in 1997 (Figure 3).40 This built upon an established 
technique known as “metabolic labelling”, whereby culture medium supplemented with 
certain non-canonical amino acids or monosaccharides allowed the incorporation of new 
functional groups into the proteome or glycome.41,42 While metabolic labelling has been used 
in its own right as a functionalization tool to modulate virus-cell interactions,43 the Bertozzi 
Group extended the scope of this technology by introducing ketones as a reactive base for 
click chemistry reactions.40 This two-step, bio-orthogonal approach provided rapid kinetics 
with high specificity (i.e. no side reactivity) under physiological conditions, as well as great 
versatility. Indeed, azides, alkynes, thiols and methacryloyls have been successfully 
incorporated into cell surface glycans,44–47 amino acids15,28,48,49 and lipids,50 with 
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applications that include the selective killing of cells,51 drug conjugation,46 cell-surface click 
gelation52 and artificial adhesion to 2D or 3D substrates.15,45 Metabolic labelling and bio-
orthogonal strategies still suffer from limitations associated with tightly regulated biosynthetic 
pathways (more of an issue for amino acids than glycans), interference from specific 
metabolic pathways (a particular issue with ketone labeling), cytotoxicity arising from certain 
mediators (such as copper ions in certain azide-alkyne reactions) and the necessity to 
include a compatible, “clickable” functional group on the secondary reactive species.53 Most 
of these issues can be overcome with careful experimental design, and metabolic labelling 
coupled with bio-orthogonal bioconjugate chemistry remains an elegant approach to cell 
functionalization. Furthermore, metabolic labelling is the only approach discussed in this 
review, other than ProtEx, that has been effectively performed in vivo.54 
Non-covalent interactions with the cytoplasmic membrane 
An extremely facile approach to cell functionalization is to generate a membrane-active 
biomaterial in isolation, rather than trying to perform in situ chemical reactions at the cell 
surface. Perhaps the simplest approach is to generate a cationic molecule that will interact 
with anionic proteoglycans present within the cell glycocalyx (Figure 2b). One of the first 
examples of this approach was reported in 1972, when Danon et al. showed that chemically-
cationised ferritin could effectively contrast label cell membranes for electron microscopy.55 
This approach used a relatively simple chemical reaction, whereby acidic amino acids on 
the protein shell were converted into non-native cationic residues via carbodiimide-mediated 
nucleophilic addition of reactive diamines. This approach was very recently applied to the 
superparamagnetic protein magnetoferritin, where hMSCs were contrast labelled for 
magnetic resonance imaging, using incubation periods as short as one minute.16 The 
magnetization of hMSCs was reduced when the biosynthesis of sulfated proteoglycans was 
significantly inhibited, which was evidence that these anionic glycocalyx species play a 
major role in mediating the electrostatic binding of chemically-cationized magnetoferritin.  
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A complementary approach, developed by the Liu Group at Harvard University, used 
aggressive site-directed mutagenesis to produce “supercharged proteins” possessing an 
unnaturally large number of charged residues.56 Here, a thermodynamically stable variant 
of the green fluorescent protein (GFP) bearing a theoretical net charge of +36 was shown 
to efficiently interact with membrane proteoglycans, and was used to deliver proteins and 
DNA to a range of different cells.57–59 Both chemical cationisation and supercharging, 
however, involve making widespread modifications to the surface of a protein, which can 
lead to conformational changes in secondary and tertiary structure and subsequent loss of 
biological activity. In general, however, cationisation represents a sound approach for 
delivering robust proteins (e.g. ferritin, GFP) to the cell membrane, however, this approach 
is likely to be challenging for more structurally sensitive proteins, while certain cationic 
species have also been shown to induce cytotoxicity via membrane thinning and hole 
formation.27 
An alternative strategy to induce artificial membrane binding is to use a hydrophobic moiety 
to anchor a species to the phospholipid bilayer (Figure 2c). A pioneering example was 
introduced by Kim and Peacock in 1993, who decorated hybridoma cells with anti-mouse 
antibodies using palmitate protein A.60 This advance was achieved by exploiting the ability 
of the palmitate lipid to intercalate with the cytoplasmic membrane, and the affinity of protein 
A for the Fc region of antibodies. Using palmitated proteins as a scaffold ensures that any 
bound antibodies are oriented away from the cell surface, which effectively presents the 
binding paratope. A decade later, this technology was adopted by the Dennis Group, who 
used palmitate protein G and tissue-specific antibodies to target chondrogenic progenitor 
cells to cartilage,61 as well as hMSCs to endothelial cells,12 the colon62 and infarcted heart 
tissue.63 In 2000, the Tykocinski Group broadened this approach beyond antibodies by 
expressing fusion proteins containing the immunoglobulin Fc region, which could specifically 
bind membrane-anchored palmitate protein A.64 Variations on this “protein transfer” 
technique have been used to induce cell-rolling by functionalizing MSCs with CD162,65 as 
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well as eliciting anti-tumor responses using an array of co-stimulators and cytokines, 
including CD80,66,67 CD254,68,69 CCL21,68,69 CD95L68 and CD137L.68,69 
In 1995, the Selvaraj and Tykocinski Groups introduced a biomimetic method known as “cell 
surface painting” using proteins recombinantly-tagged with glycosylphosphatidylinositol 
(GPI).70,71 The GPI tail, present in many native membrane-bound proteins, inserts into lipid 
raft domains in the cytoplasmic membrane and anchors the fusion protein to the cell, without 
the need for any intermediary species. Importantly, the original function of the anchored 
protein is retained, which allowed cells to be painted with a wide range of proteins, including 
CD80,70–75 CD86,71,72 CD1,76 IL-12,77 TIMP-1,78 TCR,79 CCL580 and the I-domain of 
CD11a.81 A major drawback to both protein transfer and cell surface painting is the reliance 
upon fusion proteins, which limits versatility, and can be time-consuming to prepare at 
sufficient quantities. With this in mind, a number of groups have used liposome-based 
delivery vectors to present antigens82 and synthetic membrane receptor mimics,83 increase 
the cellular association of GPI-anchored proteins,84 and provide binding sites for secondary 
species, such as biotinylated SLeX.85 Liposome-based approaches, however, are often 
limited by poor encapsulation efficiency, particularly with large biomolecular species.86 
The limitations surrounding fusion proteins and liposomes can be circumvented in several 
ways, for instance, by using synthetic glycoprotein analogues87 or metal-chelating lipids 
bearing nickel nitriloacetic acid (NTA) bound to polyhistidine-tagged proteins.88 Another, 
bioconjugation approach involves the direct covalent coupling of lipids to proteins (lipidation) 
to display hydrophobic tails such as myristyl,89,90 palmityl,90,91 stearyl,90,92 or oleyl.93–95 Here, 
the membrane affinity of lipidated proteins can be tuned to some extent by increasing the 
molecular weight of the lipid,96 while membrane persistence can be increased by using 
branched lipid tails.29 A limitation of protein lipidation, however, is the requirement of organic 
co-solvents or detergents to prevent protein aggregation. A new technology that circumvents 
these issues is “cell priming”, which uses chemically-cationized proteins electrostatically 
conjugated to a responsive poly(ethylene glycol) (PEG)-based surfactant corona. 
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Conformational rearrangement of the amphiphilic polymer surfactant promotes protein 
stability and aqueous solubility (due to the hydrophilic PEG segment),97,98 and mediates 
membrane tethering for around one week in culture (via the hydrophobic tail).13 Myoglobin 
conjugates retained their oxygen-binding capacity99 and were delivered to hMSCs to provide 
an in situ oxygen reservoir to enhance the production of matrix fibres at the centre of 
engineered cartilage constructs.13 Importantly, both cell priming and protein lipidation 
necessitate careful modification of the protein surface, as aggressive bioconjugation 
strategies can lead to denaturation and subsequent loss of biological function.100 With this 
in mind, orthogonal or site-specific modifications are an attractive option, however, these 
approaches are not feasible for all proteins. 
Extended cellular coatings  
An entirely different approach to cell functionalization is to wrap or patch cells with thin 
polymeric microsheets. For instance, agarose, carrageenan or low-methoxy pectin 
biopolymers have been used to generate a 50 µm thick gel veneer around newly-fertilized 
toad eggs.102,103 This process is an excellent example of a single-cell coating (rather than 
gel encapsulation), and was shown to be effective at preventing microbial infection and 
improving post-hatching survival rates. This study, however, was demonstrated using 
relatively large cells (diameter = 1-1.5 mm), and has not been applied to smaller cells 
(diameter <100 µm). Palchesko et al. reported a more advanced, microscale technology that 
used extracellular matrix protein sheets to “shrink wrap” endothelial cells, myoblasts and 
cardiomyocytes.30 This global coating of functional biomolecules was shown to be effective 
at modulating the structure, adhesion and behavior of the coated cells, and was used in the 
study of cell-matrix interactions. 
In 2008, the Rubner Group reported that photolithography and layer-by-layer assembly 
could be used to generate cell-binding patches of polymer104 or mucin/lectin.105 These so-
called “cell backpacks” were persistently attached to one side of T-cells and monocytes, 
respectively, and have been used to magnetize cells,104 promote non-native cellular 
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assembly,106 provide resistance to phagocytosis107 and deliver therapeutics by “hitchhiking” 
on the surface of monocytes.108 The major limitation of this approach is the requirement for 
time-consuming, layer-by-layer deposition of polymeric material, however, this was recently 
addressed by the Guan Group, who used microcontact printing as a simpler, cheaper and 
higher throughput method for generating cellular backpacks.109,110 
Discussion and new developments 
The strategies discussed above could be broadly considered as passive labelling 
technologies, whereby cells exposed to bulk media, reagents or biomaterials are 
functionalized in an indiscriminate fashion. Recently, there has been a focus on more 
controlled approaches that allow targeted delivery of discrete biomaterial payloads to 
specific areas of individual cells. In 2011, for example, the Cojoc Group reported on a new 
approach whereby liposomes were maneuvered towards the surface of individual neurons 
using optical tweezers.111,112 The optically-trapped liposomes were then ruptured, using an 
external pulse of ultraviolet radiation, which released proteins and chemical stimuli that 
directionally stimulated adjacent neurons. A similar approach was developed by the 
Perriman Group to optically deliver membrane-free coacervate microdroplets to the 
cytoplasmic membrane of MSCs (Figure 4). Here, the coacervate microdroplets were 
optimized to undergo spontaneous fusion with the cell membrane, without the need for 
external stimulation.113 Moreover, the coacervate microdroplets could be pre-loaded with 
biomolecules (e.g. proteins, nucleic acids or small molecular dyes), allowing cells to be 
“paintballed” with discrete patches of functional payload. While these approaches are 
intrinsically low throughput, with respect to total cell number, they represent extremely 
powerful diagnostic and experimental tools for site-specific or single-cell functionalization. 
In summary, it is clear that rational reconfiguration of the cytoplasmic membrane is a highly 
effective pathway to endow cells with new functionality to enhance cell-based 
biotechnologies. Indeed, the rapid pace of biotechnological advance makes this an 
opportune moment to add an extra dimension to the host of cell-based therapies at our 
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fingertips, whether this is targeting cells to diseased tissues or tumors, engineering whole 
cell vaccines, interfacing cells with materials for bioelectronics and biosensing, regenerative 
medicine, or disease modelling. What is surprising, is that cell functionalization remains an 
under-exploited tool, particularly when contrasted with the success of transfection “toolkits” 
that have made genetic manipulation a routine undertaking. This disparity may be 
rationalized, in part, by the inherently interdisciplinary nature of cell functionalization, which 
draws on expertise from disparate fields of synthetic chemistry, materials science, 
biochemistry and cell biology, and generally necessitates a more considered, bespoke 
approach. To this end, we hope that this review will serve as an aid to a greater 
understanding of the subtle differences between strategies, encourage the adoption of 
current techniques, and inspire the development of new cell functionalization 
methodologies. 
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Figure Legends 
Figure 1. Fluorescence microscopy images of functionalized cells. (a) An example of cell 
surface chemistry, with human foetal osteoblasts (nuclei labelled blue with DAPI) 
metabolically labelled with L-azidohomoalanine were conjugated to a biotinylated alkyne 
that was subsequently visualised using fluorescent streptavidin (labelled red).28 Reprinted 
(adapted) with permission from Borcard F et al. Bioconjugate Chemistry 22, 1422-32 
Copyright 2011 American Chemical Society. (b) An example of non-covalent membrane 
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labelling, in which a polyethylene glycol / oleyl chain was used to anchor proteins such as 
GFP (labelled green) into NIH3T3 cells.29 Reproduced with kind permission from John Wiley 
and Sons: Kato K, Itoh C, Yasukouchi T & Nagamune T, Biotechnology Progress, 20, 2004, 
897-904. (c) An example of an extended cellular coating, whereby matrix proteins including 
fibronectin (labelled red) were used to “shrink wrap” C2C12 cells (nuclei labelled blue with 
DAPI, actin fibres labelled in green and indicated with arrows).30 Reproduced with kind 
permission from Springer Science + Business Media: Palchesko RN, Szymanski, JM, Sahu, 
A & Feinberg, AW, Cellular and Molecular Bioengineering, 7, 2014, 335-368, Fig. 4e. 
 
Figure 2. Three broad approaches to cell membrane functionalization. (a) The first method 
is direct surface chemistry, performed on functional groups present on the cell membrane. 
Here, for instance, amine groups present on membrane proteins have been biotinylated 
(purple) to allow the addition of streptavidin (yellow). This approach is commonly used to 
deliver species labelled with streptavidin or biotin.87 (b) The second method is to increase 
the cationic surface charge of the exogenous species to facilitate attractive electrostatic 
interactions with negatively-charged moieties present predominantly within the glycocalyx. 
(c) The third strategy uses hydrophobic interactions between a conjugated lipid tail and the 
phospholipid bilayer, to anchor the exogenous species to the cell membrane. 
 
Figure 3. Metabolic labelling and biorthogonal chemistry. (a) Unnatural biomolecular 
precursors, included as cell media additives, can be taken up by cells and become 
incorporated into lipids, carbohydrates or proteins (blue), including those at the cell 
membrane. (b) Metabolic labelling can be used to present reactive groups that can bind a 
secondary species (yellow). This is usually mediated by orthogonal click chemistry, in this 
example, an alkynated secondary species is bound to a cell metabolically labelled with azide 
groups. 
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Figure 4. Cell paintballing using coacervate microdroplets. Armstrong et al. recently 
demonstrated that membrane-free coacervate microdroplets can be actively loaded with 
biomaterial payloads of protein or nucleotides, and then delivered to the cell membrane 
using optical tweezers.99 (a-e) Time-lapse bright field microscope images showing an optical 
trap (pink circle) maneuvering a GFP-loaded coacervate microdroplet towards a human 
mesenchymal stem cell to initiate a targeted fusion event. (f) Fluorescence microscopy 
revealed fluorescence emission from the GFP payload present at the site of delivery. 
 
 
